Our Smd Medical (Wuhan) Co., Ltd.

Our Smd Medical (Wuhan) Co., Ltd. specializes in teletherapy radionuclide systems designed for conventional radiotherapy. These devices are used to deliver targeted radiation therapy, primarily for oncology treatments. The company’s portfolio includes systems like the SMD-XGD/AR Galaxy and SMD Galaxy RTx, which are engineered for precision radiation delivery in clinical settings.

Our Smd Medical (Wuhan) Co., Ltd. has a presence in the United States, where it operates under regulatory frameworks governing medical radiation devices. While the company itself is based in the US, its core operations and manufacturing are rooted in Wuhan, China. The US presence ensures compliance with local regulatory standards, including those for teletherapy systems, which are critical for market access and patient safety.

Our Smd Medical (Wuhan) Co., Ltd.’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This registry is essential for tracking and identifying medical devices in the US market, ensuring transparency and traceability for regulatory oversight and patient care.

The teletherapy radionuclide systems manufactured by Our Smd Medical (Wuhan) Co., Ltd. fall under the FDA’s Class II device classification. This classification indicates a moderate level of risk, requiring special controls beyond general controls to ensure safety and effectiveness. Class II devices undergo rigorous review to validate their performance and compliance with regulatory standards.